Cartesian Therapeutics' mRNA CAR-T Descartes-08 Continues to Show Efficacy in Phase ...

Retrieved on: 2024-07-03 07:19:12

Tags for this article:

Autoimmune diseases

Food and Drug Administration

Pharmaceuticals policy

Pharmacy

Regenerative Medicine Advanced Therapy

Myasthenia gravis

B-cell maturation antigen

Lupus

Click the tags to see associated articles and topics

Cartesian Therapeutics' mRNA CAR-T Descartes-08 Continues to Show Efficacy in Phase .... View article details on hiswai:

Summary

The article discusses Cartesian Therapeutics' Descartes-08, an autologous CAR-T therapy, for treating autoimmune diseases like myasthenia gravis and lupus, highlighting positive clinical trial results and its FDA designation. This aligns with the 'regenerative medicine' concept by showcasing potential new treatments. Tags underline its relevance to specific diseases, FDA involvement, and pharmaceutical policies.

Article found on: www.cgtlive.com

View Original Article